{"id":30598,"date":"2021-01-06T07:43:37","date_gmt":"2021-01-06T07:43:37","guid":{"rendered":"https:\/\/www.neurodegenerationresearch.eu\/?p=30598"},"modified":"2021-01-06T07:48:19","modified_gmt":"2021-01-06T07:48:19","slug":"the-2021-call-of-the-eu-joint-programme-on-neurodegenerative-disease-research-jpnd-is-open","status":"publish","type":"post","link":"https:\/\/neurodegenerationresearch.eu\/sv\/2021\/01\/the-2021-call-of-the-eu-joint-programme-on-neurodegenerative-disease-research-jpnd-is-open\/","title":{"rendered":"The 2021 Call of the EU Joint Programme on Neurodegenerative Disease Research (JPND) Is Open"},"content":{"rendered":"

PARIS–(BUSINESS WIRE<\/a>)–JPND is inviting multi-national research teams to submit proposals aimed at identifying and measuring physiological effects and related biomarkers that can be linked to the development of neurodegenerative diseases.<\/strong><\/p>\n

Neurodegenerative diseases are debilitating and largely untreatable conditions that are strongly linked with age. Worldwide, there are estimated to be 47 million people suffering from Alzheimer\u2019s disease and related disorders. This figure is expected to double every 20 years as the population ages. The development of efficient treatments for most neurodegenerative diseases is hindered by the fact that their detection intervenes at late stages by which time the integrity of the nervous tissue has been compromised. Poorly characterised early physiological disturbances known to appear before unambiguous symptoms of each neurodegenerative disease are detected. These changes may include, among others, the disruption of sleep, olfaction, hearing, vision, metabolic factors as well as social engagement. All these signs have the potential to be used as early indicators of later diseases, and in most cases, are measurable in natural daily life environments. Hence, the identification of the circuits and molecular pathways being affected might reveal promising targets for early interventions and therapies for neurodegenerative diseases.<\/p>\n

In this context, JPND announced a new joint transnational call inviting multi-national research teams to submit proposals for ambitious<\/b>, innovative<\/b> and multi-disciplinary collaborative projects<\/b> that aim at the detection, measurement and understanding of early disease indicators related to neurodegenerative diseases, with potential for the development of new diagnostics or interventions.<\/p>\n

Professor Philippe Amouyel, Chair of the JPND Management Board says, \u201cOne of the major limitations of neurodegenerative diseases is their sneaky sub-clinical course that can last for years before the first symptoms appear. Very often, clinicians have noticed a posteriori that these symptoms had been preceded many years before by disturbances of major physiological functions. Thus bringing together research forces in Europe and beyond through JPND will allow us to better understand the pathophysiological mechanisms of the appearance of neurodegenerative diseases. In addition, this will help to identify early indicators of their occurrence before the neuronal potential is too altered, facilitating the implementation of treatments.\u201d<\/p>\n

Proposals submitted under this call, which is open to applicants in 22 countries<\/a>, must focus on one or several of the following neurodegenerative diseases: Alzheimer\u2019s disease and other dementias, Parkinson\u2019s disease and PD-related disorders, prion diseases, motor-neuron diseases, Huntington\u2019s disease, spinocerebellar ataxia and spinal muscular atrophy. JPND is committed to Patient and Public Involvement<\/a>, and proposals are expected to engage patients, carers and the public.<\/p>\n

Proposals must also focus on one or several of the following research areas:<\/p>\n